<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930995</url>
  </required_header>
  <id_info>
    <org_study_id>CN-05SBala-01-B</org_study_id>
    <nct_id>NCT00930995</nct_id>
  </id_info>
  <brief_title>Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C</brief_title>
  <official_title>Angiotensin Receptor Blockade an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C is the most common reason for liver transplantation in the United States and&#xD;
      affects nearly 4 million Americans. Treatments for hepatitis C are available but are poorly&#xD;
      tolerated and are not always effective. Morbidity and mortality from hepatitis C are related&#xD;
      to the development and progression of hepatic fibrosis to cirrhosis and end stage liver&#xD;
      disease. Efforts to block progression of liver disease would thus result in prevention of&#xD;
      morbidity and mortality as well as costs incurred by the health system in the care of these&#xD;
      conditions.&#xD;
&#xD;
      Scar tissue in the liver is secreted by a type of cell, called the stellate cell, in an&#xD;
      activated state. This cell carries a receptor for angiotensin, a hormone, when activated. If&#xD;
      this receptor is blocked, the cell becomes inactive and does not participate in scar tissue&#xD;
      formation. Thus, we hypothesize that using a drug such as candesartan, which blocks&#xD;
      angiotensin receptors, should result in less scar tissue formation in the livers of patients&#xD;
      with hepatitis C.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Not Awarded&#xD;
  </why_stopped>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary: • Stellate cell activity by alpha SMA stain quantitated by morphometry</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>• Hepatic fibrosis by morphometry</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surrogate markers for fibrosis (liver TGF-beta levels, serum procollagen-III peptide levels)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status- Albumin, INR, T. Bilirubin, MELD score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>16mg po daily</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Atacand</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults, age 21 and older&#xD;
&#xD;
          -  Patients with viral hepatitis C that are not on interferon based therapy.&#xD;
&#xD;
          -  Detectable viral load&#xD;
&#xD;
          -  Baseline biopsy within six months or willing to undergo biopsy prior to drug&#xD;
             initiation&#xD;
&#xD;
          -  At least grade 2 inflammation on biopsy, fibrosis of stage 1 or higher&#xD;
&#xD;
          -  Willing to undergo biopsy at the end of treatment&#xD;
&#xD;
          -  No interferon for at least 6 months prior to or after initial biopsy for study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal impairment defined by a serum creatinine of &gt;1.8&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Hepatocellular cancer&#xD;
&#xD;
          -  Concurrent treatment with pentoxyfylline, steroids, interferon alpha or interferon&#xD;
             gamma.&#xD;
&#xD;
          -  Active psychosis (affective disorders without loss of reality testing acceptable)&#xD;
&#xD;
          -  Active IV drug use&#xD;
&#xD;
          -  Prior liver transplant&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Decompensated cirrhosis as defined by the presence of ascites, hepatic encephalopathy&#xD;
             or coagulopathy with an INR&gt;1.4&#xD;
&#xD;
          -  HIV seropositivity&#xD;
&#xD;
          -  Hypotension defined by a baseline systolic blood pressure of less than 90mm of mercury&#xD;
&#xD;
          -  Contraindication to ARB use or allergy to medication&#xD;
&#xD;
          -  Treatment with potassium sparing diuretics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sripriya Subramanian, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>July 1, 2009</study_first_submitted>
  <study_first_submitted_qc>July 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2012</last_update_posted>
  <responsible_party>
    <name_title>Sripriya Balasubramanian MD MPH</name_title>
    <organization>Kaiser Permanente</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

